首页> 外文期刊>Molecular pharmaceutics >pH/Reductant Dual-Responsive Core-Cross-Linked Micelles via Facile in Situ ATRP for Tumor-Targeted Delivery of Anticancer Drug with Enhanced Anticancer Efficiency
【24h】

pH/Reductant Dual-Responsive Core-Cross-Linked Micelles via Facile in Situ ATRP for Tumor-Targeted Delivery of Anticancer Drug with Enhanced Anticancer Efficiency

机译:pH /还原剂双响应核心交联胶束通过方便的原位ATRP进行肿瘤靶向的抗癌药物传递,具有增强的抗癌效率

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Anticancer drugs cause severe side effects on normal tissues and organs due to their nonspecific delivery. Thus, tumor-targeting delivery of anticancer drugs remains a serious challenge in chemotherapy. Here a facile strategy was established for the pH/reductant dual-responsive core-cross-linked (CCL) micelles for tumor-targeted delivery of anticancer drug, via in situ atom transfer radical polymerization (ATRP). In the in vitro controlled release experiments with doxorubicin (DOX) as a model drug, the premature drug leakage rate was only 13.4% in the physiological medium within 36 h, while the cumulative release rate in the stimulated tumor microenvironment reached 78.7%, demonstrating the excellent tumor microenvironment responsive controlled release behavior upon acidic medium with high GSH level. As a folate receptor (FR) mediated targeting drug delivery system (DDS), the micelles showed excellent cytocompatibility, and enhanced anticancer efficiency after loading of DOX, compared with free DOX.
机译:抗癌药物由于其非特异性递送而对正常组织和器官造成严重的副作用。因此,抗癌药物的靶向肿瘤递送仍然是化学疗法中的严峻挑战。在这里,通过原位原子转移自由基聚合(ATRP)为pH /还原剂双响应核心交联(CCL)胶束建立了一种简便的策略,用于肿瘤靶向的抗癌药物传递。在以阿霉素(DOX)为模型药物的体外控释实验中,在36 h内生理介质中的过早药物泄漏率仅为13.4%,而在刺激的肿瘤微环境中累积释放率达到78.7%,证明了具有高GSH水平的酸性介质对肿瘤微环境有良好的响应控制释放行为。作为叶酸受体(FR)介导的靶向药物递送系统(DDS),与游离DOX相比,胶束在装载DOX后显示出优异的细胞相容性和增强的抗癌效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号